The company remains pre-revenue with no meaningful top-line generation, while R&D expenses have surged to $10.8 million in 2026Q1, reflecting the high cost of clinical development.
| Sales/Revenue | 0 | 0 | 0 | 260.5K | 123.44K | 3.1M | 698.47K | 1.12M | 4.04M | 2.06M | 967.39K |
| Revenue Growth % | - | - | -100% | 111.03% | -96.02% | 343.92% | -37.79% | -72.22% | 96.07% | 113.04% | - |
| Cost of Goods Sold | 0 | 0 | 26.27K | 13.62M | 6.72K | 11.36M | 893.8K | 2.55M | 3.65M | 1.76M | 846.39K |
| COGS % of Revenue | - | - | - | 5227.77% | 5.45% | 366.35% | 127.97% | 227.36% | 90.25% | 85.19% | 87.49% |
| Gross Profit | 0 | 0 | -26.27K | -13.36M | 116.72K | -8.26M | -195.33K | -1.43M | 393.85K | 305.25K | 121K |
| Gross Margin % | - | - | - | -5127.77% | 94.55% | -266.35% | -27.97% | -127.36% | 9.75% | 14.81% | 12.51% |
| Gross Profit Growth % | - | 100% | 99.8% | -11544.65% | 101.41% | -4127.89% | 86.34% | -463.08% | 29.03% | 152.27% | - |
| Operating Expenses | 55.59M | 51.97M | 28.56M | 6.73M | 18.25M | 6.51M | 2.62M | 4.27M | 2.12M | 2.47M | 734.29K |
| OpEx % of Revenue | - | - | - | 2584.24% | 14780.72% | 209.88% | 375.56% | 380.16% | 52.52% | 119.66% | 75.9% |
| Selling, General & Admin | 25.68M | 23.56M | 11.38M | 6.73M | 6.21M | 0 | 0 | 0 | 2.52M | 710.38K | 734.29K |
| SG&A % of Revenue | - | - | - | 2584.24% | 5031.06% | - | - | - | 62.26% | 34.47% | 75.9% |
| Research & Development | 30.12M | 29.79M | 17.21M | 13.62M | 12.03M | 11.36M | 893.8K | 2.55M | 3.65M | 1.76M | 846.39K |
| R&D % of Revenue | - | - | - | 5227.77% | 9749.66% | 366.35% | 127.97% | 227.36% | 90.25% | 85.19% | 87.49% |
| Other Operating Expenses | -209.08K | -1.37M | -26.27K | -13.62M | 0 | -4.85M | 1.73M | 1.72M | 0 | 0 | 0 |
| Operating Income | -55.59M | -51.97M | -28.59M | -20.09M | -18.13M | -14.77M | -2.82M | -5.7M | -2.12M | -405.13K | -613.29K |
| Operating Margin % | - | - | - | -7712.01% | -14686.17% | -476.23% | -403.52% | -507.52% | -52.52% | -19.66% | -63.4% |
| Operating Income Growth % | - | -81.8% | -42.31% | -10.82% | -22.77% | -423.9% | 50.54% | -168.51% | -423.81% | 33.94% | - |
| EBITDA | -54.9M | -51.91M | -28.56M | -19.91M | -18.12M | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA Margin % | - | - | - | -7643.91% | -14680.72% | - | - | - | - | - | - |
| EBITDA Growth % | -43.08% | -81.75% | -43.44% | -9.88% | - | - | - | - | - | - | - |
| D&A (Non-Cash Add-back) | 47.84K | 60.5K | 26.27K | 177.4K | 6.72K | 14.77M | 2.82M | 5.7M | 2.12M | 405.13K | 613.29K |
| EBIT | -55.8M | -53.35M | -27.52M | -20.09M | -18.05M | -14.77M | -2.82M | -5.7M | -2.12M | -405.13K | -613.29K |
| Net Interest Income | 4.26M | 3.72M | 1.07M | 1.06M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 4.26M | 3.72M | 1.07M | 1.06M | 74.45K | 19.92K | 29.4K | 24.84K | 0 | 30.95K | 15.45K |
| Interest Expense | 0 | 0 | 0 | 0 | 74.45K | 19.92K | 29.4K | 24.84K | 30.33K | 0 | 0 |
| Other Income/Expense | 4.63M | 3.72M | 1.07M | 1.06M | 74.45K | -19.92K | -29.4K | -24.84K | -30.33K | -30.95K | -15.45K |
| Pretax Income | -50.96M | -48.26M | -27.52M | -19.03M | -18.05M | -14.79M | -2.85M | -5.72M | -2.15M | -436.07K | -628.74K |
| Pretax Margin % | - | - | - | -7304.75% | -14625.85% | -476.88% | -407.73% | -509.73% | -53.27% | -21.16% | -64.99% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -50.96M | -48.26M | -27.52M | -19.03M | -18.05M | -14.79M | -2.85M | -5.72M | -2.15M | -436.07K | -628.74K |
| Net Margin % | - | - | - | -7304.75% | -14625.85% | -476.88% | -407.73% | -509.73% | -53.27% | -21.16% | -64.99% |
| Net Income Growth % | -39.43% | -75.36% | -44.62% | -5.4% | -22.1% | -419.19% | 50.24% | -165.88% | -393.6% | 30.64% | - |
| Net Income (Continuing) | -50.96M | -48.26M | -27.52M | -19.03M | -18.05M | -14.79M | -2.85M | -5.72M | -2.15M | -436.07K | -628.74K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.52 | -0.49 | -1.16 | -3.57 | -4.26 | -4.88 | -1.72 | -3.34 | -1.61 | -0.25 | -0.48 |
| EPS Growth % | 66.87% | 57.76% | 67.51% | 16.2% | 12.7% | -183.72% | 48.5% | -107.45% | -544% | 47.92% | - |
| EPS (Basic) | - | -0.49 | -1.16 | -3.57 | -4.26 | -4.88 | -1.72 | -3.34 | -1.61 | -0.25 | -0.48 |
| Diluted Shares Outstanding | 98.31M | 98.31M | 69.36M | 5.33M | 4.2M | 3.03M | 1.68M | 1.72M | 1.34M | 1.72M | 1.3M |
| Basic Shares Outstanding | 98.31M | 98.31M | 69.36M | 5.33M | 4.2M | 3.03M | 1.68M | 1.72M | 1.34M | 1.72M | 1.3M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - |
Clinical trial execution failure
As indicated by the company's financial statements, Inhibikase Therapeutics remains a pre-revenue entity, with no meaningful top-line generation recorded over the last ten quarters, underscoring the firm's current reliance on clinical development milestones rather than commercial product sales to drive future enterprise value and growth.
The absence of revenue confirms that the company is entirely in the research and development phase. Investors should interpret this as a binary outcome scenario where growth will only materialize upon the successful commercialization of its lead CNS therapeutic candidates.
Based on reported quarterly filings, R&D expenses have trended upward, reaching $10.8 million in 2026Q1, which reflects the intensifying costs associated with clinical trial enrollment and the advancement of the company's RAMP platform through critical, capital-intensive phases of the drug development lifecycle.
The volatility in R&D spending suggests that clinical trial milestones are driving the expense profile rather than a steady-state operational burn. This trend warrants close monitoring, as the company's ability to manage these costs will directly dictate the duration of its current cash runway.
As evidenced by the income statement data, the company's operating losses have widened significantly, with 2026Q1 operating losses hitting $18.2 million, demonstrating that the firm currently lacks the scale to achieve operating leverage while it continues to prioritize heavy investment in its clinical pipeline.
The lack of revenue means that every dollar spent on SG&A and R&D flows directly to the bottom line as a loss. Until the company transitions to a commercial stage, traditional operating leverage metrics remain inapplicable and investors should focus on the efficiency of capital deployment.
According to recent financial disclosures, the company has utilized stock-based compensation, including a notable $7.9 million charge in 2024Q4, which complicates the assessment of true cash-based operational costs and suggests that equity dilution remains a primary mechanism for talent retention and corporate funding.
The intermittent nature of these charges suggests that reported net losses may not fully reflect the underlying cash burn rate of the business. Analysts should adjust for these non-cash items to better understand the actual liquidity requirements of the firm's ongoing research activities.
While the company maintains a substantial cash position, the rapid acceleration of quarterly net losses to $16.4 million in 2026Q1 suggests that the current cash runway could be shorter than anticipated if clinical trial timelines face further delays or unexpected regulatory hurdles.
The primary risk is that the company may be forced to raise capital in a dilutive manner if the current burn rate persists without a corresponding valuation re-rating from positive clinical data. This creates a potential conflict between the need for long-term research and the immediate pressure of capital preservation.
Quick answers to the most common questions about buying IKT stock.
For fiscal year 2025, Inhibikase Therapeutics, Inc. (IKT) reported total revenue of $0.0M. This represents a 100.0% decline compared to $1.0M in 2016.
Inhibikase Therapeutics, Inc. (IKT) reported a net loss of $48.3M for the fiscal year ending 2025.